CA2755694A1 - Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell - Google Patents

Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell Download PDF

Info

Publication number
CA2755694A1
CA2755694A1 CA2755694A CA2755694A CA2755694A1 CA 2755694 A1 CA2755694 A1 CA 2755694A1 CA 2755694 A CA2755694 A CA 2755694A CA 2755694 A CA2755694 A CA 2755694A CA 2755694 A1 CA2755694 A1 CA 2755694A1
Authority
CA
Canada
Prior art keywords
amino acid
cyaa
polypeptide
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2755694A
Other languages
English (en)
French (fr)
Inventor
Peter Sebo
Adriana Osickova
Jiri Masin
Catherine Fayolle
Jan Krusek
Marek Basler
Claude Leclerc
Radim Osicka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Microbiology CAS
Institute of Physiology CAS
Institut Pasteur
Original Assignee
Institute of Microbiology CAS
Institute of Physiology CAS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09155929.4A external-priority patent/EP2233569B1/en
Priority claimed from US12/409,324 external-priority patent/US8017132B2/en
Application filed by Institute of Microbiology CAS, Institute of Physiology CAS, Institut Pasteur filed Critical Institute of Microbiology CAS
Publication of CA2755694A1 publication Critical patent/CA2755694A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2755694A 2009-03-23 2010-03-23 Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell Abandoned CA2755694A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/409,324 2009-03-23
EP09155929.4 2009-03-23
EP09155929.4A EP2233569B1 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
US12/409,324 US8017132B2 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
PCT/EP2010/053795 WO2010136231A1 (en) 2009-03-23 2010-03-23 MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL

Publications (1)

Publication Number Publication Date
CA2755694A1 true CA2755694A1 (en) 2010-12-02

Family

ID=42224889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2755694A Abandoned CA2755694A1 (en) 2009-03-23 2010-03-23 Mutant cyaa polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Country Status (7)

Country Link
EP (1) EP2411513B1 (enExample)
JP (1) JP5770711B2 (enExample)
CN (2) CN105602924A (enExample)
CA (1) CA2755694A1 (enExample)
ES (1) ES2612945T3 (enExample)
RU (1) RU2585216C2 (enExample)
WO (1) WO2010136231A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
WO2018091613A1 (en) * 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (en) * 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3381931A1 (en) 2017-03-29 2018-10-03 Mikrobiologicky ustav AV CR, v.v.i. Adenylate cyclase toxoid with reduced cytolytic activity
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
FR2638169B1 (fr) * 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
EP1715047A3 (en) 1992-04-21 2008-08-27 Institut Pasteur Recombinant mutants for inducing specific immune responses
FR2805544B1 (fr) * 2000-02-28 2004-07-16 Pasteur Institut Adenylcyclase recombinante et procede de tri de molecules a activite proteolytique utilisant cette adenylcyclase
ES2331348T3 (es) * 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
WO2005035557A2 (en) * 2003-10-14 2005-04-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
PT1576967E (pt) * 2004-03-18 2007-12-03 Pasteur Institut Proteína recombinante que transporta epitopos do virús do papilloma humano inseridos numa proteína adenilato ciclase, ou no seu fragmento, e seus usos terapêuticos

Also Published As

Publication number Publication date
EP2411513A1 (en) 2012-02-01
WO2010136231A1 (en) 2010-12-02
JP2012521207A (ja) 2012-09-13
RU2585216C2 (ru) 2016-05-27
RU2011138706A (ru) 2013-04-27
CN105602924A (zh) 2016-05-25
CN102439146A (zh) 2012-05-02
ES2612945T3 (es) 2017-05-19
EP2411513B1 (en) 2016-11-09
JP5770711B2 (ja) 2015-08-26

Similar Documents

Publication Publication Date Title
US9708596B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
AU2017331949B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US9957301B2 (en) Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response
EP2411513B1 (en) MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL
US20210113678A1 (en) Antigenic Peptides For Prevention And Treatment Of Cancer
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
US10688165B2 (en) Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
EP4045150B1 (en) Immunogenic compounds for treatment of adrenal cancer
US8017132B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
Sun et al. Engineering the Immune Adaptor Protein STING as a Biologic
Li A milk protein-hitchhiking strategy for the oral delivery of amphiphilic vaccines
KR20210108418A (ko) 암의 치료 또는 예방에 사용하기 위한 식세포성 입자
Howland Yeast-based vaccine approaches to cancer immunotherapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150126

FZDE Dead

Effective date: 20190730